Abstract
Introduction Respiratory Syncytial Virus (RSV) is a major cause of morbidity in older adults. With the emergence of the coronavirus disease 2019 (COVID-19) and the subsequent changes in respiratory viral circulation, it is crucial to reassess RSV-associated healthcare burden in adults. This study assessed RSV-associated healthcare burden in adults in six European countries before and during the COVID-19 pandemic.
Methods We conducted a retrospective analysis using national hospital admissions data from Denmark, England, Finland, the Netherlands, Scotland, and regional surveillance data from the Valencia region (Spain). We included patients aged ≥18 years hospitalised for respiratory tract infections (RTIs) from 2016 to 2023. We assessed RSV-coded and laboratory-confirmed hospitalisations, intensive care unit (ICU) admissions, in-hospital length of stay (LOS), and mortality.
Results RSV-associated hospitalisations significantly reduced during the 2020/2021 season across all countries, coinciding with strict COVID-19 preventive measures, but resurged in subsequent seasons. We observed the highest hospitalisation rates in adults aged ≥85 years. RSV-coded hospitalisations were found to underestimate the true burden when compared with laboratory-confirmed cases. Underestimation factors ranged from 1.1 to 4.3 times across countries. No significant differences were observed in LOS or ICU admission rates for RSV-associated hospitalisations compared to RTIs.
Discussion Our findings underscore the complex epidemiology of RSV in older adults. The differences between RSV-coded and laboratory-confirmed cases highlight the critical need for improved surveillance and diagnostic practices to better assess the true burden. Our findings could be vital for guiding public health strategies, particularly with the recent introduction of RSV vaccines for older adults.
Competing Interest Statement
AUF, MvB, TL, and DG report no conflicts of interest. ROY reports a research contract from AstraZeneca. CKJ reports a research grant from Nordsjaellands Hospital, travel grants from the University of Copenhagen, William Demants Fond in Denmark, and the European Society of Clinical Virology and expert consultation fees from Sanofi outside of the submitted work. OJ and RK are Sanofi employees and may hold stock shares. RAC is an employee of GSK and holds financial equities in GSK shares. AOS has attended several congresses whose registration, travel, and accommodation costs were covered by MSD, GSK, AZ, and Sanofi Pasteur (SP). TKF reports honoraria for panel participation and conference presentation from GSK and Pfizer with 100% own decision on content. TH reports payment or honoraria from Pfizer for lecture at an academic meeting and participation in Ad hoc advisory board meeting for Pfizer. HN reports personal fees from Pfizer, GSK, Sanofi, Novavax and Merck. HC reports grants from NIHR Global Health Unit funding and Baszucki Brain Research Foundation, consulting fees from WHO (Geneva), membership of academic/educational committees of RSE, Acad MedSci, and UK Research Excellence Framework outside the submitted work.
Funding Statement
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 101034339. This Joint Undertaking received support from the European Union Horizon 2020 research and innovation programme and EFPIA. The funding source organised the collaboration and received final report on the project. The funding source had no influence of the scientific content of the project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All countries participating in this study received ethical and/or institutional board approvals to access and utilise national and/or regional health registries.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Shared first authorship
